Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Etanercept vs Sulphasalazine in Ankylosing Spondylitis
NCT00247962Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Primary completion
- Feb 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 18
01
Overview
Phase 4, randomised, double-blind trial of etanercept in ankylosing spondylitis (AS), sponsored by Pfizer. Primary endpoint: Assessment in Ankylosing Spondylitis 20 Response at 16 weeks. Started Dec 2005; status: completed.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00247962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247962.